Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Leukemia & Lymphoma
|
July 15, 2016
Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma
Natalie Galanina, Jagoda Jasielec, David Peace, et al.
Clinical and Translational Science
|
October 17, 2013
Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy
Chris E Holmes, Jagoda Jasielec, Jamie E Levis, et al.
Seminars in Oncology
|
October 19, 2013
Evolving strategies in the initial treatment of multiple myeloma
Cara Rosenbaum, Jagoda Jasielec, Jacob Laubach, et al.
Blood Cancer Journal
|
August 10, 2020
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
Benjamin A Derman, Jagoda Jasielec, Spencer S Langerman, et al.
European Journal of Haematology
|
February 2, 2023
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
Benjamin A Derman, Ajai Chari, Jeffrey Zonder, et al.
Leukemia & Lymphoma
|
February 9, 2021
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Ajay Major, Jennifer Collins, Caroline Craney, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 2, 2020
Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic
Amin Virani, Zachary Schlei, Christine Gleason, et al.
British Journal of Haematology
|
March 4, 2020
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy
Ajai Chari, Dan T Vogl, Sundar Jagannath, et al.
Leukemia & Lymphoma
|
May 13, 2022
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies
Ola Landgren, Dickran Kazandjian, Murielle Roussel, et al.
Blood Advances
|
February 10, 2023
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
Benjamin A Derman, Jeffrey Zonder, Donna Reece, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Leukemia & Lymphoma
|
July 15, 2016
Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma
Natalie Galanina, Jagoda Jasielec, David Peace, et al.
Clinical and Translational Science
|
October 17, 2013
Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy
Chris E Holmes, Jagoda Jasielec, Jamie E Levis, et al.
Seminars in Oncology
|
October 19, 2013
Evolving strategies in the initial treatment of multiple myeloma
Cara Rosenbaum, Jagoda Jasielec, Jacob Laubach, et al.
Blood Cancer Journal
|
August 10, 2020
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
Benjamin A Derman, Jagoda Jasielec, Spencer S Langerman, et al.
European Journal of Haematology
|
February 2, 2023
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
Benjamin A Derman, Ajai Chari, Jeffrey Zonder, et al.
Leukemia & Lymphoma
|
February 9, 2021
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature
Ajay Major, Jennifer Collins, Caroline Craney, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 2, 2020
Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic
Amin Virani, Zachary Schlei, Christine Gleason, et al.
British Journal of Haematology
|
March 4, 2020
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy
Ajai Chari, Dan T Vogl, Sundar Jagannath, et al.
Leukemia & Lymphoma
|
May 13, 2022
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies
Ola Landgren, Dickran Kazandjian, Murielle Roussel, et al.
Blood Advances
|
February 10, 2023
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
Benjamin A Derman, Jeffrey Zonder, Donna Reece, et al.
Page
of 2